As monother­a­py da­ta dis­ap­point, Cyteir lets go of 35 staffers, goes all in on ovar­i­an can­cer

Over the sum­mer, as the biotech blues dragged on and de­pressed Cyteir Ther­a­peu­tics shares, ex­ecs de­cid­ed to post­pone clin­i­cal plans for a sec­ond can­di­date and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER